The cytokine TGF-β allows tumors to evade the immune system by converting conventional natural killer cells into type 1 innate lymphoid cells devoid of cytotoxic function.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Artis, D. & Spits, H. Nature 517, 293–301 (2015).
Gury-BenAri, M. et al. Cell 166, 1231–1246 (2016).
Gao, Y. et al. Nat. Immunol. 18, 1004–1015 (2017).
Cortez, V.S. et al. Nat. Immunol. 18, 995–1003 (2017).
Cortez, V.S. et al. Immunity 44, 1127–1139 (2016).
Denney, L. et al. Immunity 43, 945–958 (2015).
Ikushima, H. & Miyazono, K. Nat. Rev. Cancer 10, 415–424 (2010).
Dadi, S. et al. Cell 164, 365–377 (2016).
Crome, S.Q. et al. Nat. Med. 23, 368–375 (2017).
Pikovskaya, O. et al. J. Immunol. 196, 1449–1454 (2016).
Robinette, M.L. et al. Nat. Immunol. 16, 306–317 (2015).
Simoni, Y. et al. Immunity 46, 148–161 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.S.S. and A.A.H. are full-time employees of MedImmune and hold shares in AstraZeneca.
Rights and permissions
About this article
Cite this article
Silver, J., Humbles, A. NK cells join the plasticity party. Nat Immunol 18, 959–960 (2017). https://doi.org/10.1038/ni.3817
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni.3817